Biosimilar Substitution Can Reduce TCOC, Improve Provider Performance in Value-Based Payment Models

A simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model.

Related Keywords

United States ,American , ,Oncology Care Model ,Enhancing Oncology Model ,Oncology Care ,Medicare Oncology Care Model ,American Journal ,Managed Care ,Biosimilars ,Oncology ,Medicare ,Total Cost Of Care ,